News & Updates

New drug applications approved by US FDA as of 01 - 15 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Drug combinations including venetoclax seem to have a positive impact on health-related quality of life (HRQoL), or at least does not worsen it, in patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, a recent study has found.

For patients who have undergone continuous‐flow left ventricular assist device (CF‐LVAD) implantation, treatment with amiodarone may do more harm than good, with a recent study showing that it contributes to increased risk of mortality.

Adjuvant therapy with 5-fluorouracil (5-FU) and low molecular weight heparin in high-risk patients with rhegmatogenous retinal detachment (RRD) does not help prevent the development of proliferative vitreoretinopathy, as shown in a study.

In patients with gout and end-stage renal disease (ESRD), haemodialysis appears to have an additional benefit of lowering uric acid (UA) levels, a study has found.

The use of pranlukast in infants with respiratory syncytial virus (RSV) infections appears to help avoid the need for respiratory support, a recent Japan study has found.

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.